A Multicenter Phase 2 Study Evaluating the Optimized Schedule of Belantamab Mafodotin 1.9 Mg/Kg Q8W Plus Bortezomib and Dexamethasone in Relapsed Refractory Multiple MyelomaTereza Popkova,Jakub Radocha,Martin Stork,Jiří Minařík,Jan Straub,Alexandra Jungova,Petr Pavlicek,Tomas Jelinek,Vladimir Maisnar,Ludek Pour,Tomas Pika,František Sedlák,Jan Soukup,Hana Plonkova,Ludmila Muronova, Viera Sandecka,Petra Krhovska,David Zihala,Roman HajekBlood（2024）引用 0|浏览6AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
